Pfiz­er/Spark team gets a ‘break­through’ in gene ther­a­py al­liance

A cou­ple of years ago, Pfiz­er set up a new group to tack­le the hot gene ther­a­py field, draft­ing Michael Lin­den from King’s Col­lege to get it go­ing. Right off the bat, the phar­ma gi­ant al­so teamed with Spark Ther­a­peu­tics – a hot play­er in the gene ther­a­py field – to part­ner on an ex­per­i­men­tal pro­gram for he­mo­phil­ia B. And now the part­ners can boast of a ‘break­through’ drug des­ig­na­tion at the FDA to help speed their work along.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.